Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression 

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.

BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

 team as an assistant editor in 2025 after previously working on the 

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

OncLive News Network

An Update on Immunotherapy in Liver Cancer

Videos

Recent Advances in the Treatment of Liver Cancer 

Hepatocellular Carcinoma: Immunotherapy After Sorafenib 

Hepatocellular Carcinoma: Recent Approval of Nivolumab

KEYNOTE-224: Improving HCC Outcomes With Pembrolizumab 

Optimizing Checkpoint Inhibitor Combinations in HCC 

Hepatocellular Carcinoma: Future Role of Immunotherapy 

An Update on Immunotherapy in Liver Cancer

Latest Conference Coverage